Pfizer (PFE) Change in Cash (2009 - 2026)

Pfizer (PFE) has reported Change in Cash for 18 consecutive years, with -$727.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Cash fell 441.31% year-over-year to -$727.0 million in Q2 2026; TTM through Jun 2026 was -$661.0 million, a 20.74% increase from a year earlier, with the FY2025 full-year figure at $91.0 million, up 105.03% from the prior year.
• Change in Cash was -$727.0 million for Q2 2026 at Pfizer, down from $563.0 million in the prior quarter.
• Over five years, Change in Cash peaked at $1.8 billion in Q2 2023 and troughed at -$2.1 billion in Q1 2024.
• A 5-year average of -$134.1 million and a median of $8.5 million in 2025 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash jumped 3626.67% in 2022 and sank 441.31% in 2026, its largest moves.
• Over 5 years, Change in Cash stood at -$688.0 million in 2022, then surged by 54.07% to -$316.0 million in 2023, then slumped by 458.54% to -$1.8 billion in 2024, then surged by 88.9% to -$196.0 million in 2025, then plunged by 270.92% to -$727.0 million in 2026.
• The last three Change in Cash figures came in at -$727.0 million (Q2 2026), $563.0 million (Q1 2026), and -$196.0 million (Q4 2025), per Business Quant data.